The results revealed a substantial improvement in median progression-free survival (mPFS) and overall survival (OS) that led to the approval of osimertinib as the preferred first-line therapy for NSCLC harboring EGFR Ex19del or L858R mutations.14 This evidence concerns the gene EGFR and non-small cell lung carcinoma.